This product is not prepared for cell culture applications.
Please see the following products below which are tested for cell culture use:
https://www.sigmaaldrich.com/product/sigma/d4902
https://www.sigmaaldrich.com/product/sigma/d2915
D-085
Dexamethasone solution
1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Empirical Formula (Hill Notation):
C22H29FO5
CAS Number:
Molecular Weight:
392.46
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.24
Pricing and availability is not currently available.
Recommended Products
grade
certified reference material
Quality Level
form
liquid
feature
Snap-N-Spike®/Snap-N-Shoot®
packaging
ampule of 1 mL
manufacturer/tradename
Cerilliant®
concentration
1.0 mg/mL in methanol
technique(s)
gas chromatography (GC): suitable
liquid chromatography (LC): suitable
application(s)
clinical testing
format
single component solution
storage temp.
−20°C
SMILES string
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
InChI
1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1
InChI key
UREBDLICKHMUKA-CXSFZGCWSA-N
Gene Information
human ... NR3C1(2908)
General description
Dexamethasone is a potent glucocorticoid which acts as an anti-inflammatory and immunosuppressant for therapeutic treatments in many inflammatory and autoimmune conditions, oncology, and endocrine diseases such as Addison′s disease. Dexamethasone levels in serum or plasma are measured by LC-MS/MS for dexamethsaone suppression tests or monitoring dexamethsaone treatment regimens. This Certified Spiking Solution® is suitable for use as starting materials in the preparation of calibrators and controls for dexamethasone testing methods by LC-MS/MS.
Application
- Controlled drug delivery systems: Hydrogel microneedles incorporating dexamethasone demonstrate a programmed mesophase transition, optimizing the controlled release of drugs for therapeutic applications. This advancement in drug delivery technology illustrates the utility of dexamethasone solution in developing innovative pharmaceutical materials (Dawud et al., 2024).
- Enhanced nasal drug administration: Bovine Serum Albumin nanoparticles, integrated with dexamethasone, highlight a novel gelling system designed to enhance nasal drug delivery. This research underscores the potential of dexamethasone solution in creating more effective and patient-friendly drug delivery modalities (Mardikasari et al., 2023).
- Sustained-release formulations: The development of polyvinyl alcohol microparticles for the sustained release of dexamethasone via a coaxial microfluidic system demonstrates the critical role of dexamethasone solution in producing precision drug delivery systems that improve therapeutic efficacy and patient compliance (Abdi Majareh et al., 2023).
- Topical drug delivery for ocular conditions: Dexamethasone-loaded chitosan nanoparticles were developed for topical application in a rabbit model of endotoxin-induced uveitis, indicating significant advancements in localized drug delivery systems using dexamethasone solutions. This application is particularly relevant in treating inflammatory eye diseases with enhanced drug delivery efficiency (Alkholief et al., 2023).
Legal Information
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
related product
Product No.
Description
Pricing
Signal Word
Danger
Hazard Statements
Precautionary Statements
Hazard Classifications
Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
Target Organs
Eyes,Central nervous system
Storage Class Code
3 - Flammable liquids
WGK
WGK 2
Flash Point(F)
49.5 °F - closed cup
Flash Point(C)
9.7 °C - closed cup
Choose from one of the most recent versions:
Certificates of Analysis (COA)
Lot/Batch Number
It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.
If you need assistance, please contact Customer Support.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
Erich Piovan et al.
Cancer cell, 24(6), 766-776 (2013-12-03)
Glucocorticoid resistance is a major driver of therapeutic failure in T cell acute lymphoblastic leukemia (T-ALL). Here, we identify the AKT1 kinase as a major negative regulator of the NR3C1 glucocorticoid receptor protein activity driving glucocorticoid resistance in T-ALL. Mechanistically
Fausto Roila et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32(2), 101-106 (2013-12-11)
A combination of aprepitant, a 5-HT3 receptor antagonist, and dexamethasone is recommended for the prophylaxis of acute or delayed emesis induced by chemotherapy containing anthracyclines plus cyclophosphamide in patients with breast cancer. The aim of this study was to verify
Peter Bärtsch et al.
The New England journal of medicine, 368(24), 2294-2302 (2013-06-14)
A 45-year-old healthy man wishes to climb Mount Kilimanjaro (5895 m) in a 5-day period, starting at 1800 m. The results of a recent exercise stress test were normal; he runs 10 km 4 or 5 times per week and
Valentina Proserpio et al.
Genes & development, 27(11), 1299-1312 (2013-06-12)
Elucidating the epigenetic mechanisms underlying muscle mass determination and skeletal muscle wasting holds the potential of identifying molecular pathways that constitute possible drug targets. Here, we report that the methyltransferase SMYD3 modulates myostatin and c-Met transcription in primary skeletal muscle
María-Victoria Mateos et al.
The New England journal of medicine, 369(5), 438-447 (2013-08-02)
For patients with smoldering multiple myeloma, the standard of care is observation until symptoms develop. However, this approach does not identify high-risk patients who may benefit from early intervention. In this randomized, open-label, phase 3 trial, we randomly assigned 119
-
Is this formulation prepared for cell culture applications ?
1 answer-
Helpful?
-
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service
